Thrombosis News Ticker
Follow the Thrombosis News Ticker on
-
CLOTS 3: Inflatable Leg Sleeves Reduce DVT in Stroke
Intermittent pneumatic compression with inflatable sleeves that fit over the legs reduced the occurrence of deep vein thrombosis (DVT) in immobile patients who had had a recent stroke in the CLOTS 3 study.
-
Beta-blockers benefit heart surgery cases
Using beta-blockers after heart surgery reduces the risk of dangerous abnormal heart rhythms, according to a analysis. One complication after heart surgery is atrial fibrillation (AF), where the two upper chambers of the heart quiver, rather than beating effectively.
-
Rivaroxaban Gains Approval In Europe For ACS Indication
Rivaroxaban […] has been approved in Europe for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction or stroke) following an acute coronary syndrome (ACS). The drug was approved at a dose of 2.5 mg twice-daily and should be used in combination with standard antiplatelet therapy. Rivaroxaban is now the only oral anticoagulant to receive an ACS indication.
-
Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
These contemporary observational worldwide data on non-valvular atrial fibrillation, collected at the end of the vitamin K antagonist-only era, indicate that these drugs are frequently not being used according to stroke risk scores and guidelines, with overuse in patients at low risk and underuse in those at high risk of stroke.
-
Systematic screening for atrial fibrillation 'better than routine GP practice'
Systematic screening in GP practices for atrial fibrillation could identify more people with the disease than routine practice, according to a gold-standard review.
-
Antiplatelet Effects of Aspirin: Which NSAIDs Interact?
Low-dose aspirin is widely used as prevention for myocardial infarction and other cardiovascular diseases, but there is evidence that concurrent use of NSAIDs may inhibit the antiplatelet effect of aspirin.
-
Repeat ablation wins out over antiarrhythmic agents for recurrent paroxysmal AF
Should recurrences after a failed ablation in patients with paroxysmal atrial fibrillation (AF) be treated with antiarrhythmic drugs (AAD) or with a repeat pulmonary vein isolation (PVI) procedure? More likely second time's the charm, suggests a randomized trial showing that repeat ablation is much more likely than AAD to get rid of a recurrence.
-
'Clean' Vessels Seen in Some Young MI Patients
Although young patients with acute coronary syndromes typically carry traditional cardiovascular risk factors, some of them show no evidence of underlying coronary artery disease, researchers found.
-
7 simple lifestyle steps may lower risk of blood clot
Adopting seven simple lifestyle steps could help reduce your risk of these potentially deadly blood clots, according to a new study.
-
ESC guide on new oral anticoagulant drugs
A practical guide on the use of the new oral anticoagulants (NOACs) has been produced by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). A guide was needed to summarise existing information on different drugs, to answer clinical questions that fall outside what drug companies can legally answer, and to make distinctions between the different drugs.
-
ACS assessment tools released by ACP
In an effort to better the lives of patients in the first year after an initial acute coronary syndrome (ACS) event, the American College of Physicians (ACP) has released a pair of evidence-based interventions and two videos for clinicians and patients to heed.
-
Anticoagulant Boosts Benefit of Antiplatelet After Stenting
Add-on anticoagulant therapy after stent deployment for acute coronary syndromes (ACS) significantly reduced the risk of stent thrombosis and mortality in patients already receiving dual antiplatelet therapy, according to a new analysis of a large randomized trial.
-
LAFB associated with long-term cardiovascular and mortality risk
Left anterior fascicular block (LAFB), an electrocardiographic abnormality previously considered benign, is associated with a significantly increased long-term risk of atrial fibrillation (AF), congestive heart failure, and death, according to the results of a new analysis published April 16, 2013 in the Journal of the American Medical Association.
-
ACP unveils tools to improve health outcomes in patients following ACS event
Interventions aim to improve health outcomes in patients after blood flow to heart muscle is suddenly blocked.
-
Steriod use doubles risk of venous thromboembolism
Glucocorticoids may increase the risk of venous thromboembolism (VTE), irrespective of how they are administered, suggests a large, population-based case–control study from Denmark.
-
New Drugs Better Value Than Warfarin
The three newest anticoagulants -- dabigatran […], apixaban […], and rivaroxaban […] -- are cost-effective relative to warfarin for preventing stroke in patients with nonvalvular atrial fibrillation, researchers found.
-
Stent type may influence thrombosis rates in patients with diabetes
Everolimus-eluting stents are associated with lower rates of stent thrombosis compared with paclitaxel-eluting stents in those with diabetes, but after adjustment, the composite rate of target lesion revascularization major adverse events was similar between stent types at 1 year, study results have concluded.
-
Women experiencing still birth are more likely to develop blood clots, says study
Women who have suffered a still birth or have medical conditions including varicose veins, inflammatory bowel disease (IBD) or heart disease are at greater risk of developing dangerous blood clots after giving birth, a study has revealed.
-
European committee adopts positive opinion on rivaroxaban for ACS
The Committee for Medicinal Products for Human Use has adopted a positive opinion for expanding the indication of rivaroxaban to include patients with ACS, according to a press release issued by the agency.
-
Thrombosis publications recommended by the Board of Advisers has been updated for February 2013.
New Thrombosis publications available for February 2013.
-
Pregnancy-associated plasma protein A predicts cardiovascular events: Study
Higher levels of pregnancy-associated plasma protein A (PAPP-A) were associated with an increased risk of cardiovascular events in people with cardiac chest pain that developed as a result of heart disease/coronary artery disease, according to a study published in CMAJ.
-
Vena cava filter use may vary widely between hospitals
The use of vena cava filters in patients with acute venous thromboembolism varied widely in California hospitals, not only according to clinical indications but also after adjusting for important confounders such as the hospital size, rural location and type of hospital.
-
Irregular heartbeat treatment inadequate in US, study finds
A significant number of U.S. patients with irregular heart rhythms do not receive adequate therapy, according to a new study of treatment practices for atrial fibrillation.
-
ACC: Extra-Long Plavix Course No Help After Stenting
The risk of cardiac death, MI, or stroke was the same whether patients stayed on aspirin plus clopidogrel for at least 36 months or shifted to aspirin alone after 12 months, Cheol Whan Lee, MD, of Asan Medical Center in Seoul, South Korea, and colleagues found.
-
More Than 100,000 Americans Die Annually as a Result of Deep Vein Thrombosis (DVT) and Pulmonary Embolism
More than 900,000 Americans each year have a deep vein thrombosis or pulmonary embolism episode which can result in damage to their lungs or other organs and can be fatal. The CHEST Foundation, as part of its OneBreath Initiative, announced the launch of kNOw DVT, a month-long awareness effort that features a series of online resources developed by the American College of Chest Physicians to help educate consumers affected by DVT or who are looking to learn more.
-
Cangrelor more effective than clopidogrel in preventing blood clots
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. These data, from the phase III CHAMPION PHOENIX study, were presented at the American College of Cardiology's 62nd Annual Scientific Session and published simultaneously in the New England Journal of Medicine.
-
Net Clinical Benefit of Rivaroxaban for Thrombosis Prevention in ACS Patients
After reports of having met the primary endpoints in the ATLAS-ACS TIMI-51 study, rivaroxaban 2.5mg and 5mg demonstrated a benefit over placebo in terms of cardiac mortality and bleeding risk as presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.
-
On-Admission High-Dose Rosuvastatin Prevents Contrast-Induced Nephropathy in Acute Coronary Syndrome
Statin-naïve patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) scheduled for early invasive procedures who receive high-dose rosuvastatin on admission have a significantly lower incidence of contrast-induced acute kidney injury (CI-AKI) and a reduction in 30-day adverse clinical events, according to results of the PRACTO-ACS study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.
-
Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
Janssen Research & Development, LLC (Janssen) today announced the launch of EXPLORER, a comprehensive, global research program for […] (rivaroxaban), an oral anticoagulant. The program includes studies […] for investigational use in patients with chronic heart failure and in those with coronary artery disease or peripheral artery disease.
-
Major risks of dual and triple antithrombotic therapy in patients with newly diagnosed atrial fibrillation
Patients with atrial fibrillation are at an increased risk of ischemic stroke. In this high-risk population, vitamin K antagonists such as warfarin have been shown to be highly effective in preventing this event. However, the afflicted often receive multiple antithrombotic drugs such as warfarin in combination with aspirin and clopidogrel to manage their associated cardiovascular conditions.
-
Thrombosis publications recommended by the Board of Advisers has been updated for December 2012.
New Thrombosis publications available for December 2012.
-
Simple Method Devised for Determining Atrial Fibrillation Risk in Women
Atrial fibrillation is the most common type of abnormal heart rhythm, affecting 2.5 million Americans. If left undetected or untreated, atrial fibrillation can lead to stroke. Determining who is at increased risk for atrial fibrillation has been difficult, especially among individuals without established heart disease.
-
WOEST supports clopidogrel only in PCI patients on anticoagulation
Publication of the WOEST trial results reaffirm the study's major finding that antiplatelet therapy with clopidogrel alone is preferable to the use of both aspirin and clopidogrel in patients undergoing percutaneous coronary intervention (PCI) who are receiving oral anticoagulant therapy.
-
Heightened stroke risk for patients with sleep apnea and atrial fibrillation
Atrial fibrillation (AF) may play an intermediary role in the relationship between obstructive sleep apnea (OSA) and stroke, research findings suggest.
-
CHADS scores possibilities extend beyond atrial fibrillation
The CHADS-based risk scores can predict long-term vascular outcomes and mortality in patients with stroke who do not have atrial fibrillation (AF), research suggests.
-
Higher risks for patients with secondary AF diagnosis
Patients with atrial fibrillation who present to the emergency department for other conditions have a higher risk of death than patients who present with atrial fibrillation as their primary diagnosis, according to the results of a new analysis.
-
ASCO GU: Anticoagulant use predicts metastatic prostate CA survival
Anticoagulant use is associated with improved overall survival in men receiving docetaxel chemotherapy for treatment of metastatic castration-resistant prostate cancer (mCRPC), according to research presented at the American Society of Clinical Oncology's annual Genitourinary Cancers Symposium […].
-
Two Drugs Similar in VTE Recurrence Rate
Dabigatran-treated patients had a recurrent VTE rate of 1.8% versus 1.3% with warfarin in a trial involving 2,856 patients with a history of VTE.
-
Antiplatelet Switch Still Has Bleeding Risks
Switching high-risk patients to clopidogrel […] can help counteract the low platelet reactivity common with prasugrel […], but doing so has risks of its own, a first-of-its-kind study found.
-
Prolonged ambulatory cardiac monitoring improved AF detection, treatment after cryptogenic stroke
Prolonged ambulatory cardiac monitoring after a cryptogenic ischemic stroke or transient ischemic attack appears to be a more effective method for detecting occult atrial fibrillation than standard methods.
-
MAGELLAN published: Rivaroxaban reduces VTE risk in acutely ill patients
First presented at the American College of Cardiology (ACC) 2011 Scientific Sessions by lead investigator Dr Alexander Cohen (King's College, London, UK) […], the study shows that rivaroxaban is noninferior to standard 10-day treatment with enoxaparin for the prevention of asymptomatic proximal or symptomatic venous thromboembolism (VTE) at day 10 and is superior to enoxaparin for the prevention of the same clinical events at day 35.
-
European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
The registry plans to gather data from more than 4,000 patients with VTE across seven European countries, providing insights into the clinical management of a disease that is a leading cause of morbidity and mortality.
-
Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy
The development of new antithrombotic agents for the treatment of ACS and other cardiovascular diseases is a rapidly evolving and increasingly complex field. Optimizing the prevention of ischaemic events and simultaneously minimizing bleeding risks are central to improving patient outcomes.
-
Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type
ABO blood type had an additive effect on the risk of venous thromboembolism when combined with factor V Leiden R506Q and prothrombin G20210A mutations; blood type was the most important risk factor for venous thromboembolism in the general population.
-
New stroke guidelines stress need for fast treatment
New guidelines on stroke care stress that getting clot-busting drugs and other treatments within one hour of arriving in the emergency room is crucial to minimizing brain damage and speeding recovery.
-
Patient variables affected outcomes between prasugrel, clopidogrel
ACS patients treated with prasugrel experience fewer ischemic complications but more bleeding than those receiving clopidogrel, and individualized thienopyridine selection could maximize the benefits and safety of these drugs, results from a recent study suggest.
-
A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats
Prasugrel and ticagrelor showed several differences on their pharmacological profiles and their disparity may reflect their different reversibility and/or pharmacokinetic profiles.
-
Ultrasound strategy excludes DVT in pregnant women
Serial compression ultrasonography with iliac vein visualization can reliably exclude deep vein thrombosis (DVT) in symptomatic pregnant women, according to results from an 8-year prospective cohort study published in the Canadian Medical Association Journal.
-
In STEMI, C-Reactive Protein at Presentation Predicts MI, Death
For patients with ST-segment elevation myocardial infarction, high-sensitivity C-reactive protein measurements at presentation predict subsequent nonfatal myocardial infarction and cardiac death; and for patients with acute coronary syndromes, fetuin-A and C-reactive protein have prognostic value, according to two studies published in the Jan. 1 issue of The American Journal of Cardiology.
-
Atrial fibrillation increases risk of kidney failure in people with CKD
Many people who suffer from chronic kidney disease progressively lose their kidney function over time and eventually develop a condition called end-stage renal disease - the complete failure of the kidneys - placing them in need of lifelong dialysis or a kidney transplant.
-
Venous Thromboembolism, PE Risk Up in IVF Pregnancies
Pregnant women have an increased risk of venous thromboembolism and pulmonary embolism after in vitro fertilization (IVF), especially during the first trimester, according to a study published online Jan. 15 in BMJ.
© 2013, Bayer Pharma AG
This website is intended to provide information to an international audience outside the USA and UK.
G.GM.XA.03.2013.0183
UK users please click here.